Antibiogram
Generated by OpenEvidence.com 27Jun2025
| Organism | Antibiotic | % Susceptible (Range) | Notes (if any) |
|---|---|---|---|
| Staphylococcus aureus | Oxacillin (Methicillin) | ~58–62 | MRSA prevalence varies by region |
| Vancomycin | 100 | No resistance detected in recent surveys | |
| Clindamycin | ~20 | High resistance in some settings | |
| Erythromycin | ~10–20 | High resistance | |
| Linezolid | 100 | No resistance detected | |
| Escherichia coli | Ampicillin | ~10–44 | High resistance |
| Ceftriaxone | ~60–90 | ESBL rates affect susceptibility | |
| Ciprofloxacin | ~70–95 | Lower in inpatient settings | |
| Nitrofurantoin | ~87 | Good for urinary isolates | |
| Imipenem/Meropenem | >95 | Carbapenem resistance rare but increasing | |
| Klebsiella pneumoniae | Ampicillin | 0 | Intrinsic resistance |
| Ceftriaxone | ~50–90 | ESBL rates variable | |
| Ciprofloxacin | ~60–90 | Variable by region | |
| Imipenem/Meropenem | ~50–95 | Carbapenemase-producers increasing | |
| Pseudomonas aeruginosa | Piperacillin-tazobactam | ~93 | Resistance <10% in most settings |
| Ceftazidime | ~93 | Resistance <10% | |
| Ciprofloxacin | ~80–94 | Lower in inpatient settings | |
| Amikacin | ~98 | High susceptibility | |
| Enterococcus faecalis | Ampicillin | 100 | High-level gentamicin resistance ~43% |
| Vancomycin | ~97 | VRE rare but present | |
| Linezolid | 100 | No resistance detected | |
| Proteus mirabilis | Nitrofurantoin | 0 | Intrinsic resistance |
| Ceftriaxone | ~20–90 | Variable resistance | |
| Acinetobacter baumannii | Carbapenems | <10 | High resistance in ICU settings |